Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1

Conditions

Urinary Bladder Neoplasms 1Smoking Cessation 1Prostatic Neoplasms 1Hematuria 1Carcinoma, Transitional Cell 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urinalysis × Genitourinary × Clear all
NCT05646485 2026-05-01

Bladder Cancer Screening Trial

University of Texas Southwestern Medical Center

Phase NA Recruiting
1,000 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Hematuria, Smoking Cessation

NCT03568188 2026-02-24

FOCALE

Hospices Civils de Lyon

Phase 2 Completed
174 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡